Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Tests of online PrEP purchases by London clinic find no fakes, and adequate drug levels

A sexual health clinic in central London that offered to test drug levels in users of tenofovir/emtricitabine pre-exposure prophylaxis (PrEP) who had bought it online found adequate

Published
26 October 2016
By
Gus Cairns
Two Thirds of Oral PrEP-Using MSM Would Switch to Long-Term Shots

One third of men who have sex with men (MSM) using daily oral PrEP for a year or more would "definitely switch" to a long-acting PrEP shot every 3 months, while another third would "probably switch," according to results of a 90-man survey. Hispanic and nonwhite men were significantly more likely to be among definite switchers.

Published
26 October 2016
From
NATAP
More Surprises From ÉCLAIR: Cabotegravir's 'Long Tail'

The long-acting injectable cabotegravir (ViiV Healthcare), a novel HIV prevention therapy, can persist in the body for more than a year in some people, surprising new data from the phase 2a ÉCLAIR study show. "It's an important finding because you need to give patients some sense of when that protection ends," said Jeanne Marrazzo, MD, from the University of Alabama at Birmingham.

Published
26 October 2016
From
Medscape (requires free registration)
The benefit of treatment has outweighed the clinical impact of lipodystrophy, conference hears

The 2016 International Congress on Drug Therapy in HIV Infection (HIV Glasgow) heard today that over a 20-year period, people who suffered lipodystrophy (fat redistribution) and

Published
26 October 2016
By
Gus Cairns
Dolutegravir and central nervous system side-effects: abacavir, older age increase the risk

Insomnia, dizziness, headache and other central nervous system side-effects are occurring more frequently with everyday use of dolutegravir than clinical trials had suggested, and are most likely to

Published
25 October 2016
By
Keith Alcorn
Two-drug HIV therapy just as effective as three-drug therapy

Simplification of an antiretroviral treatment to a boosted protease inhibitor and the nucleoside analogue lamivudine (a dual regimen) is highly effective in people switching from a stable three-drug

Published
25 October 2016
By
Keith Alcorn
New nanomedicine approach aims to improve HIV drug therapies

New research led by the University of Liverpool aims to improve the administration and availability of drug therapies to HIV patients through the use of nanotechnology.

Published
24 October 2016
From
Science Daily
Huge diversity in current HIV vaccine research, Research for Prevention conference hears

The HIV vaccine research field is currently going through probably its most fertile and diverse period yet, the second HIV Research for Prevention conference (HIVR4P) in Chicago

Published
23 October 2016
By
Gus Cairns
Gene therapy goes global: Portable device could make future cancer, HIV cures affordable

A tabletop device that enables medical staff to genetically manipulate a patient’s blood to deliver potential new therapies for cancer, HIV and other diseases would eliminate the need for multimillion-dollar “clean rooms,” making gene therapy more possible for even the poorest of countries.

Published
21 October 2016
From
Fred Hutchinson Cancer Research Center
Rings, films or inserts? Researchers need to develop prevention products that make sense in women’s lives

“We need to think outside of the box,” Sharon Hillier of the Microbicide Trials Network told the HIV Research for Prevention (HIVR4P 2016) conference in Chicago

Published
21 October 2016
By
Roger Pebody

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.